Travere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 21,977 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 21,977 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $41.07, for a total transaction of $902,595.39. Following the sale, the chief accounting officer directly owned 42,353 shares of the company’s stock, valued at approximately $1,739,437.71. This represents a 34.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sandra Calvin also recently made the following trade(s):

• On Tuesday, February 3rd, Sandra Calvin sold 4,333 shares of Travere Therapeutics stock. The shares were sold at an average price of $32.12, for a total transaction of $139,175.96.

Travere Therapeutics Stock Down 3.4%

Shares of TVTX stock opened at $39.54 on Friday. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $43.31. The stock has a market cap of $3.65 billion, a P/E ratio of -131.80 and a beta of 0.86. The company has a current ratio of 2.74, a quick ratio of 2.70 and a debt-to-equity ratio of 2.71. The company has a 50 day simple moving average of $29.77 and a two-hundred day simple moving average of $31.42.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in FSGS, materially expanding Travere’s rare‑kidney franchise and adding an estimated ~30,000 U.S. patients to the addressable market — the core reason for the earlier, large share price gain. Filspari approval article
• Positive Sentiment: Market reaction and analyst upgrades lifted sentiment and targets (examples: Canaccord, Guggenheim, Piper Sandler, HC Wainwright), reinforcing a re‑rating narrative and supporting higher medium‑term revenue expectations for Filspari. Guggenheim note
• Neutral Sentiment: Trading activity is elevated and options volumes spiked around the approval — this amplifies short‑term moves (both up and down) and suggests greater volatility while the market digests label details and early commercialization assumptions. Options activity report
• Neutral Sentiment: Company commentary and coverage (conference/transcript writeups, health press) are clarifying the label and launch plans, but concrete revenue/volume reads are not yet available — useful for modeling but not definitive. Company discussion
• Negative Sentiment: Multiple insiders (CEO, directors, CFO, other executives) sold material blocks of shares over the last two trading days — most sales were executed under pre‑arranged Rule 10b5‑1 plans or to cover taxes related to vesting, but the scale of selling can fuel near‑term downward pressure and signal profit‑taking after the approval‑driven rally. Example SEC filing for CEO sale. CEO Form 4
• Negative Sentiment: Some analysts warn that estimate‑revision trends and elevated expectations could limit near‑term upside — the stock may consolidate or pull back as investors re‑rate forward revenue assumptions. Zacks caution

Hedge Funds Weigh In On Travere Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. State of Wyoming bought a new position in shares of Travere Therapeutics during the fourth quarter worth $37,000. Torren Management LLC bought a new position in shares of Travere Therapeutics during the fourth quarter worth $38,000. Comerica Bank boosted its position in shares of Travere Therapeutics by 77.5% during the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after acquiring an additional 492 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Travere Therapeutics by 69.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock worth $45,000 after acquiring an additional 487 shares during the last quarter. Finally, First Horizon Corp bought a new position in shares of Travere Therapeutics during the third quarter worth $36,000.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a research report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. JPMorgan Chase & Co. dropped their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. Wall Street Zen lowered shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $42.50.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.